Evidence map›Paper›PMID 33660192›Full record

ArticleInternational journal of clinical pharmacy2021

Impact of severe oral mucositis in pediatric cancer patients on resource utilization and cancer treatment plans.

Farah Alsheyyab, Deema Al-Momani, Rawan Kasht, Aya Kamal, Dana Abusalem, Wiam Al-Qasem

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in International journal of clinical pharmacy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06623305 (Photobiomodulation Therapy for the Prevention of Mucositis in Pediatric Oncology Patients), which is not on this map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06623305 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

Photobiomodulation Therapy for the Prevention of Mucositis in Pediatric Oncology Patients

TypeinterventionalSponsorMedical College of WisconsinRan2026 to 2027Enrolled50ConditionsMucositis OralArmsPhotobiomodulation for prevention arm, Photobiomodulation for exploratory arm
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Anti-inflammatory mouthwashes for the prevention of oral mucositis in cancer therapy: an integrative review and meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022
    Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Farah AlsheyyabKing Hussein Cancer Center, Department of Pharmacy, Queen Rania St 202, Amman, 11941, Jordan. FA.12504@KHCC.JO.ORCID http://orcid.org/0000-0002-7050-2810
Deema Al-MomaniKing Hussein Cancer Center, Department of Pharmacy, Queen Rania St 202, Amman, 11941, Jordan.
Rawan KashtKing Hussein Cancer Center, Department of Pharmacy, Queen Rania St 202, Amman, 11941, Jordan.
Aya KamalKing Hussein Cancer Center, Department of Pharmacy, Queen Rania St 202, Amman, 11941, Jordan.
Dana AbusalemKing Hussein Cancer Center, Department of Pharmacy, Queen Rania St 202, Amman, 11941, Jordan.
Wiam Al-QasemKing Hussein Cancer Center, Department of Pharmacy, Queen Rania St 202, Amman, 11941, Jordan.
King Hussein Cancer Center · JO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOral mucositis is a common chemotherapy-related adverse event that may result in serious complications. Few studies have evaluated mucositis in pediatric patients.

objectiveTo evaluate the impact of severe mucositis on resource utilization and on treatment plans of pediatric cancer patients.

settingComprehensive cancer center in Amman, Jordan.

methodRetrospective study on pediatric patients undergoing active cancer treatment with a hospital admission diagnosis of severe oral mucositis (January 2015-December 2019). Patients undergoing bone marrow transplant were excluded. Severe oral mucositis was defined as interfering with oral intake and requiring intravenous opioids.

main outcome measureWe reviewed the electronic billing system and patient medical charts to determine the resources utilized during hospitalization, cost, and the impact on subsequent treatment protocols.

resultsDuring the study period, 200 patients were eligible; the average age was 8.6±5.6 years (SD) and 45% had acute lymphoblastic leukemia. The median hospital stay was 6 days (range 2-21) with a total median cost of US$ 2,176 (range 635-13,976) per admission. The median medication cost was US$ 1,075 (range 135-9010), and 85% of the patients received antibiotics during hospitalization, at a median cost of US$ 487 (range 23-2,193). Modification of the chemotherapy treatment protocol was required in 110 patients, which included dose reduction (60%), delay (38%), and discontinuation (2%).

conclusionSevere oral mucositis is associated with significant resource utilization and modification of the treatment protocols. Further studies are needed to identify strategies to reduce the impact of mucositis in this patient population.

Indexed as

NeoplasmsStomatitisAdolescentChildHospitalizationHumansLength of StayRetrospective StudiesAntineoplastic protocolDrug costsHospital costsMucositisPediatricsStomatitis

Identifiers

PMID33660192
OpenAlexW3134466060

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.